| Orencia (abatacept) / BMS |
| Completed | N/A | 422 | US | | Bristol-Myers Squibb | Rheumatoid Arthritis | 07/10 | 07/10 | | |
| Completed | N/A | 5451 | US | | Bristol-Myers Squibb | Rheumatoid Arthritis | 08/10 | 08/10 | | |
NCT01339481: A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept |
|
|
| Completed | N/A | 26 | US | abatacept, Orencia | Astellas Pharma Inc, Perseid Therapeutics LLC | Rheumatoid Arthritis | 10/11 | 10/11 | | |
NCT02600468: Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg |
|
|
| Completed | N/A | 671 | Japan | Orencia | Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd | Rheumatoid Arthritis | 12/15 | 12/15 | | |
NCT02598466: Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa |
|
|
| Completed | N/A | 69 | RoW | Abatacept | Bristol-Myers Squibb, Hexor, South Africa | Rheumatoid Arthritis | 01/16 | 01/16 | | |
| Completed | N/A | 2364 | Canada, Europe | Abatacept, Orencia | Bristol-Myers Squibb | Rheumatoid Arthritis | 02/16 | 02/16 | | |
|
|
NCT01583244: Korean Post-marketing Surveillance for Orencia® |
|
|
| Completed | N/A | 701 | RoW | No Intervention (subjects were previously treated with Orencia®), Abatacept | Bristol-Myers Squibb | Rheumatoid Arthritis | 02/16 | 02/16 | | |
NCT02600455: Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL |
|
|
| Completed | N/A | 505 | Japan | Orencia | Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd | Rheumatoid Arthritis | 06/16 | 06/16 | | |
NCT01088321: Safety Study of Abatacept to Treat Rheumatoid Arthritis (A) |
|
|
| Completed | N/A | 81332 | US, RoW | | Bristol-Myers Squibb | Rheumatoid Arthritis | 11/16 | 11/16 | | |
NCT01555879: Real-world Clinical Efficacy of Abatacept in the T3 Data Registry |
|
|
| Completed | N/A | 200 | US | Abatacept, Orencia Intravenous | Arthritis Northwest PLLC, Bristol-Myers Squibb | Arthritis, Rheumatoid | 11/16 | 11/16 | | |
NCT02169544: Post-marketing Study Assessing the Long-Term Safety of Abatacept |
|
|
| Completed | N/A | 100000 | NA | Abatacept | Bristol-Myers Squibb | Rheumatoid Arthritis | 02/17 | 02/17 | | |
NCT02632890: Assessment of the Effectiveness of IV and SC Abatacept (Orencia) Patient Alert Cards in Patients With Rheumatoid Arthritis in a Sample of EU Countries |
|
|
| Completed | N/A | 203 | Europe | | Bristol-Myers Squibb | Rheumatoid Arthritis | 04/17 | 04/17 | | |
NCT02885818: Does Abatacept Induce Regulatory B Cells in Patients With Rheumatoid Arthritis |
|
|
| Completed | N/A | 20 | Europe | | University Hospital, Brest | Rheumatoid Arthritis | 01/18 | 01/18 | | |
| Completed | N/A | 153 | NA | Abatacept | Bristol-Myers Squibb | Rheumatoid Arthritis | 01/18 | 01/18 | | |
NCT01694693: Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study |
|
|
| Withdrawn | N/A | 0 | NA | Orencia | Bristol-Myers Squibb | Rheumatoid Arthritis | 12/18 | 12/18 | | |
NCT01088360: Safety Study of Abatacept to Treat Rheumatoid Arthritis (B) |
|
|
| Active, not recruiting | N/A | 20000 | NA | | Bristol-Myers Squibb, National Data Bank for Rheumatic Diseases (NDB) | Rheumatoid Arthritis | 06/29 | 06/29 | | |
